Nanolek donated a medication for the treatment of cardiovascular diseases to the Kirov Centre for Cardiology and Neurology.
The Kirov Regional Clinical Center of Cardiology and Neurology, a municipal state-funded public health institution, is expected to receive 84 thousand packs of Nebivolol NANOLEK® 5 mg No. 30 (INN: Nebivolol) worth 10 million rubles. The drug has already arrived at the warehouses of the Kirov Regional State Unitary Enterprise “Aptechny sklad” .
Nebivolol NANOLEK® is a third-generation cardioselective beta-adrenergic antagonist with vasodilator properties. It is used in arterial hypertension, coronary heart disease, angina of effort.
In Russia, as elsewhere in the world, cardiovascular diseases are still the leading cause of morbidity and mortality, despite medical and preventive measures. According to Rosstat, deaths caused by cardiovascular causes have declined steadily since 2010: in 2017, 862,895, or 587.6 people per 100,000 population died of such diseases vs 1,151,917, or 806.4 people per 100,000 population in 2010. However, cardiovascular diseases (CVDs) are still the leading cause of death in Russia, accounting for almost half (47%) of all deaths.
Patient health and safety is a priority for Nanolek that takes every effort to offer patients only high-quality medicines. Nanolek’s primary mission is to protect lives and health of people by making the world’s best technology available to everyone. The Nanolek’s biopharmaceutical complex is located in the Kirov region, therefore it helps prevent and protect local inhabitants’ health and meet the current demand for medicines. The company has undertaken the obligation to deliver the medicines. Nanolek’s initiatives comply with Article 2 of Federal Law No. 135-FZ of 11 August 1995 “On charitable activity and volunteering” and Article 582 of the Civil Code of the Russian Federation.
The Biopharmaceutical Complex in the Kirov region has been producing Nebivololol-NANOLEK® 5 mg No. 30 since 2015. On average, 80,000 packages are produced per year.
Dmitry Viktorovich Khrushch, Candidate of Medical Sciences, surgeon, senior medical manager at Nanolek:
“Beta-blockers are used in many cardiovascular disease treatment regimens. They have proven to reduce statistically CVD mortality rates, especially in older patients, as they target different links in pathogenetic processes. Beta-blockers are the “gold standard” in the treatment of cardiovascular diseases, have proven positive effects on the body and helped to save many lives.”
Mikhail Sergeevich Nekrasov, General Director of Nanolek:
“Our company’s mission is to save people’s lives and health; something we do not just say, but work every day. Cardiovascular diseases are world’s No. 1 killer. That is why efficient drugs are the first-choise “weapon” in the hands of the Russian doctors who save our fellow citizens every day. By joining our efforts only we would be able to extend life expectancy in the population. We are glad to have the resources to help.”
For your reference:
Arterial hypertension (AH, arterial hypertension, hypertension) is a long-term medical condition in which the blood pressure (BP) persistently exceeds 130/80 mmHg at physical and emotional rest and without exposure to any external factors.
The prevalence of hypertension in the adult population is 30-45%. In Russia, prevalence of AH is slightly higher among men aged 25-65 years (up to 47% in some regions), whereas prevalence of AH among women is appr. 40%. Prevalence of AH increases with age and reaches 60% or more in those over 60 years of age. The number of people affected by hypertension is predicted to increase by 15-20% to almost 1.5 billion by 2025.
AH is a higher risk for cardiovascular (myocardial infarction, stroke, coronary heart disease (CHD), chronic heart failure), cerebrovascular (ischaemic or haemorrhagic stroke, transient ischaemic attack) and renal (chronic kidney disease (CKD)) diseases as compared to other factors.
An elevated blood pressure is the leading global cause of premature death and nearly 10 million deaths and more than 200 million disabilities worldwide.
Source: ” Arterial Hypertension In Adults” Clinical Guidelines. Clinical guideline developed by: All-Russian public organization “Russian Society of Cardiology”. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation.
Coronary heart disease (CHD) is myocardial damage due to impaired supply of blood through the coronary arteries (CAs). CHD occurs as a result of organic (irreversible) and functional (transient) changes.
Coronary heart disease is the leading cause of CVD deaths. The annual CHD mortality rate in Russia is 27%. Importantly, 42% of all CHD deaths account for the working-age population. Patients diagnosed with stable angina are twice as likely to die of CHD as patients living without it. Meanwhile, only 40-50% of all CHD patients are aware of the disease they have and receive appropriate treatment, whereas 50-60% of cases go undiagnosed.
The prevalence of angina as the most common CHD form in the population increases with age: from 5-7% in women aged 45-64 years to 10-12% in women aged 65-85 years, and from 4-7% in men aged 45-64 years to 12-14% in men aged 45-64 years.
Source: “Stable Coronary Heart Disease” Clinical Guidelines. Clinical guidelines developed by: the Russian Society of Cardiology. Collaborators: National Society for the Study of Atherosclerosis, National Society of Atherothrombosis, Association of Cardiovascular Surgeons of Russia. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation.
Nanolek is a state-of-the-art biopharmaceutical company, a leader in the production of pediatric vaccines in Russia. Vladimir Khristenko and Mikhail Nekrasov founded the company in 2011. The company focuses on the production of import-substituting and innovative drugs, both proprietary and co-developed with international partners. The portfolio includes vaccines, medicines for the treatment of HIV, cancer and orphan diseases.